Results 141 to 150 of about 26,283,235 (262)

Clinical laboratory COVID-19 response call : February 7, 2022

CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19).

core  

Clinical laboratory COVID-19 response call : November 30, 2020 [PDF]

CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19).

core  

Automated extraction of standardized antibiotic resistance and prescription data from laboratory information systems and electronic health records: a narrative review. [PDF]

Front Antibiot
Cappello A, Murgia Y, Giacobbe DR, Mora S, Gazzarata R, Rosso N, Giacomini M, Bassetti M.   +7 more
europepmc   +1 more source

Extracellular matrix remodeling and immune reprogramming drive residual tumor progression of liver cancer after incomplete microwave ablation

Molecular Oncology, EarlyView.
Incomplete microwave ablation (iMWA) of liver cancer triggers a biphasic progression in residual tumors. At Day 3, the microenvironment is characterized by acute inflammatory responses and extracellular matrix (ECM) remodeling. By Day 14, a profound shift occurs toward oncogenic signal transduction and immunosuppression, marked by macrophage ...
Yu Liu, Yubei He, Nikolaus Berndt, Michael Mülleder, Kathrin Textoris‐Taube, Jing Guo, Matthias Stechele, Justus Ramtke, Shraga Nahum Goldberg, Lynn Jeanette Savic   +9 more
wiley   +1 more source

Clinical laboratory COVID-19 response call : October 04, 2021 [PDF]

CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19).

core  

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source

Clinical laboratory COVID-19 response call : April 13, 2020

CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19).

core  

Clinical laboratory COVID-19 response call : August 23, 2021 [PDF]

CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19).

core  

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Clinical laboratory COVID-19 response call : April 6, 2020

CDC\u2019s Division of Laboratory Systems (DLS) convenes regular calls with clinical laboratories to discuss the nation\u2019s clinical laboratory response to coronavirus disease (COVID-19).

core